Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quisinostat with Chemotherapy in NSCLC and Ovarian Cancer
NCT02728492Phase 1Completed
- Sponsor
- NewVac
- Start
- Aug 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of quisinostat in non-small cell lung cancer (NSCLC) and epithelial ovarian cancer (EOC) (7 arms), sponsored by NewVac. Primary endpoint: Safety and tolerability of Quisinostat at 22 weeks. Started Aug 2013; status: completed.
02
Drugs
quisinostat
03
Conditions
non-small cell lung cancer (NSCLC)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT02728492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728492.